Evolution of the Average Target: Autolus Therapeutics plc

Evolution of the Average Target - Autolus Therapeutics plc

Evolution of the Target Price: Autolus Therapeutics plc

Evolution of the Target Price - Autolus Therapeutics plc

Changes in Analyst Recommendations: Autolus Therapeutics plc

2ad4.I22hyJgNQGrzX5jXggM7hdQ0BvFogSq6v8Mz6Tjw0BQ.ewXW-sI0JFi_ANG62ztu0YtfNYcwsVyJjrkF3UDAoWJ7LOujwlU6C7s4wQ~c0921b45b182ab6086460487910574d8
03-31 Mizuho Cuts Price Target on Autolus Therapeutics to $10 From $12, Keeps Outperform Rating MT
01-13 Truist Adjusts Price Target on Autolus Therapeutics to $8 From $10, Maintains Buy Rating MT
01-13 Truist Cuts Price Target on Autolus Therapeutics to $8 From $10, Keeps Buy Rating MT
31/03/25 Truist Adjusts Price Target on Autolus Therapeutics to $10 From $11, Maintains Buy Rating MT
18/11/24 Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7 MT
15/11/24 Redburn Atlantic Upgrades Autolus Therapeutics to Buy From Neutral, Price Target is $13 MT
18/03/24 Truist Securities Adjusts Price Target on Autolus Therapeutics to $10 From $9, Keeps Buy Rating MT
12/02/24 Needham Adjusts Autolus Therapeutics Price Target to $9 From $8, Maintains Buy Rating MT
22/01/24 Needham Adjusts Autolus Therapeutics' Price Target to $8 From $7, Maintains Buy Rating MT
13/12/23 Goldman Sachs Raises Price Target on Autolus Therapeutics to $4.80 From $3.20, Maintains Neutral Rating MT
09/11/23 Deutsche Bank Initiates Coverage on Autolus Therapeutics With Buy Rating, $10 Price Target MT
17/08/23 Truist Securities Adjusts Price Target on Autolus Therapeutics to $9 From $6, Maintains Buy Rating MT
05/05/23 Wells Fargo Adjusts Price Target on Autolus Therapeutics to $6 From $8, Maintains Overweight Rating MT
27/03/23 Wells Fargo Assumes Autolus Therapeutics at Overweight With $8 Price Target MT
08/03/23 Mizuho Adjusts Price Target on Autolus Therapeutics to $12 From $18, Maintains Buy Rating MT
09/12/22 Needham Lowers Price Target on Autolus Therapeutics to $7 From $12, Maintains Buy Rating MT
23/08/22 Truist Securities Trims Autolus Therapeutics' Price Target to $10 From $11, Maintains Buy Rating MT
14/06/22 Truist Securities Adjusts Price Target for Autolus Therapeutics to $11 From $13, Maintains Buy Rating MT
20/12/21 HC Wainwright Adjusts Autolus Therapeutics' Price Target to $11 From $13, Reiterates Buy Rating MT
24/08/21 Autolus Therapeutics : Goldman Sachs Adjusts Price Target on Autolus Therapeutics to $5.50 From $9.50, Maintains Neutral Rating MT
14/06/21 Autolus Therapeutics : Jefferies Lifts Autolus Therapeutics to Buy From Hold, Price Target to $12 From $6 MT
06/05/21 Autolus Therapeutics : Needham & Co Adjusts Autolus Therapeutics PT to $21 From $26, Maintains Buy Rating MT
10/03/21 Autolus Therapeutics : Redburn Downgrades Autolus Therapeutics to Neutral from Buy MT
29/01/21 Autolus Therapeutics : JPMorgan Downgrades Autolus Therapeutics to Neutral From Overweight, Adjusts Price Target to $9 From $24 MT
07/01/21 Autolus Therapeutics : HC Wainwright Adjusts Autolus Therapeutics' Price Target to $13 From $19, Keeps at Buy MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+416.27%
+9.87%
+9.83%
-0.31%
+7.65%
-0.65%
-1.09%
+29.22%
-7.35%
+1.57%
Average +46.50%
Weighted average by Cap. +6.47%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.720USD
Average target price
8.725USD
Spread / Average Target
+407.27%
High Price Target
11.00USD
Spread / Highest target
+539.53%
Low Price Target
5.000USD
Spread / Lowest Target
+190.70%

Analyst Consensus Detail

Analyst consensus - Autolus Therapeutics plc

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Autolus Therapeutics plc
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Autolus Therapeutics plc
  1. Stock Market
  2. Stocks
  3. AUTL Stock
  4. Consensus Autolus Therapeutics plc